A proposed structural classification of cardiac actin mutations may help integrate structural information with pathogenesis to develop targeted treatments for hypertrophic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
ACTC1 mutation classification by location remains hypothesis-generating; prospective validation needed before clinical use.
Mutations in the cardiac actin gene (ACTC1) are associated with the development of hypertrophic cardiomyopathy (HCM). To date, 12 different ACTC1 mutations have been discovered in patients with HCM. Given the high degree of sequence conservation of actin proteins and the range of protein-protein interactions actin participates in, mutations in cardiac actin leading to HCM are particularly interesting. Here, we suggest the classification of ACTC1 mutations based on the location of the resulting amino acid change in actin into three main groups: 1) those affecting only the binding site of the myosin molecular motor, termed M-class mutations, 2) those affecting only the binding site of the tropomyosin regulatory protein, designated T-class mutations, and 3) those affecting both the myosin- and tropomyosin-binding sites, called MT-class mutations. To understand the precise pathogenesis of cardiac actin mutations and develop treatments specific to the molecular cause of disease, we need to integrate rapidly-growing structural information with studies of regulated actomyosin systems.
No takes yet. Share an insight, caveat, or question.
Despond et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: